New drug may be formidable adversary for hard to treat leukemia

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients. A new study published in the February issue of Cancer Cell reveals how detailed information about the action of an existing drug was used to design a compound that is effective against some notoriously treatment resistant cancer cases.

Despite the resounding success of anticancer drug imatinib (Gleevec) as a treatment of chronic myeloid leukemia (CML), a small but growing number of patients develop resistance to the drug and relapse. Imatinib inhibits the activity of Bcr-Abl, a protein that is abnormally active in most CML patients. Relapse and resistance to imatinib in patients with advanced disease is linked to the emergence of additional mutant forms of Bcr-Abl that are not inhibited by imatinib.

A group led by Dr. James D. Griffin from the Dana-Farber Cancer Institute working with scientists at Novartis Pharma AG in Switzerland used data obtained from structural examination of the molecular interaction between imatinib and Abl to design AMN107, a compound that has a stronger and more complete molecular association with Abl. AMN107 effectively blocked proliferation of Bcr-Abl dependent cells derived from CML patients and was an even more potent inhibitor of Bcr-Abl than imatinib. Importantly, AMN107 inhibited the growth of cells expressing many Bcr-Abl mutants that were resistant to imatinib and oral administration of AMN107 prolonged survival in imatinib-resistant CML mouse models.

Phase I clinical trials with AMN107 have just started. "If human clinical trials validate the effectiveness of AMN107 demonstrated in the preclinical studies reported here, it may be possible to either use AMN107 in selected patients with imatinib resistance, or to use both agents together, simultaneously or sequentially," says Dr. Griffin. The researchers are h

Contact: Heidi Hardman
Cell Press

Page: 1 2

Related biology news :

1. Learning to fight an adversary that wont stay down
2. New system of wastewater treatment could reduce the size of treatment plants by half
3. Brain blood flow gives clues to treating depression
4. UCF research links proteins, stem cells and potential Alzheimers treatment
5. New strategy for treating allergic disorders
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: